Losartan

"Losartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.

Descriptor ID	D019808
MeSH Number(s)	D02.455.426.559.389.185.475 D03.383.129.308.507 D03.383.129.617.467
Concept/Terms	Losartan Losartan 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol DuP-753 DuP-753 DuP 753 DuP753 MK-954 MK-954 MK 954 MK954 Cozaar Cozaar Losartan Potassium Losartan Potassium Potassium, Losartan Losartan Monopotassium Salt Monopotassium Salt, Losartan Salt, Losartan Monopotassium

Below are MeSH descriptors whose meaning is more general than "Losartan".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Benzene Derivatives [D02.455.426.559.389]
Biphenyl Compounds [D02.455.426.559.389.185]
Losartan [D02.455.426.559.389.185.475]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Imidazoles [D03.383.129.308]
Losartan [D03.383.129.308.507]
Tetrazoles [D03.383.129.617]
Losartan [D03.383.129.617.467]

Below are MeSH descriptors whose meaning is related to "Losartan".

Below are MeSH descriptors whose meaning is more specific than "Losartan".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Losartan" by people in this website by year, and whether "Losartan" was a major or minor topic of these publications.

Bar chart showing 17 publications over 14 distinct years, with a maximum of 2 publications in 2009 and 2010 and 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2003	1	0	1
2005	0	1	1
2009	2	0	2
2010	0	2	2
2012	1	1	2
2013	1	0	1
2014	0	1	1
2015	1	0	1
2017	0	1	1
2018	0	1	1
2021	0	1	1
2022	0	1	1
2023	0	1	1

Below are the most recent publications written about "Losartan" by people in Profiles.

Ferreira JP, Zannad F, Kiernan MS, Konstam MA. High- versus low-dose losartan and uric acid: An analysis from HEAAL. J Cardiol. 2023 07; 82(1):57-61.

View in: PubMed
Ferreira JP, Konstam M, Rossignol P, Kiernan MS, Zannad F. High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL. J Card Fail. 2023 01; 29(1):45-52.

View in: PubMed
Wang EY, Kuzmanov U, Smith JB, Dou W, Rafatian N, Lai BFL, Lu RXZ, Wu Q, Yazbeck J, Zhang XO, Sun Y, Gramolini A, Radisic M. An organ-on-a-chip model for pre-clinical drug evaluation in progressive non-genetic cardiomyopathy. J Mol Cell Cardiol. 2021 11; 160:97-110.

View in: PubMed
Silva LS, Peruchetti DB, Silva-Aguiar RP, Abreu TP, Dal-Cheri BKA, Takiya CM, Souza MC, Henriques MG, Pinheiro AAS, Caruso-Neves C. The angiotensin II/AT1 receptor pathway mediates malaria-induced acute kidney injury. PLoS One. 2018; 13(9):e0203836.

View in: PubMed
Silva RMD, Chaves GC, Chaves LA, Campos MR, Luiza VL, Bertoldi AD, Ross-Degnan D, Emmerick ICM. Farm?cia Popular Program: pharmaceutical market analysis of antihypertensive acting on the renin-angiotensin system medicines. Cien Saude Colet. 2017 Aug; 22(8):2501-2512.

View in: PubMed
Vohra R, Accorsi A, Kumar A, Walter G, Girgenrath M. Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A). PLoS One. 2015; 10(9):e0138254.

View in: PubMed
Kiernan MS, Gregory D, Sarnak MJ, Rossignol P, Massaro J, Kociol R, Zannad F, Konstam MA. Early and late effects of high- versus low-dose angiotensin receptor blockade on renal function and outcomes in patients with chronic heart failure. JACC Heart Fail. 2015 Mar; 3(3):214-23.

View in: PubMed
Bang CN, Gerdts E, Aurigemma GP, Boman K, de Simone G, Dahl?f B, K?ber L, Wachtell K, Devereux RB. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients. Circ Cardiovasc Imaging. 2014 May; 7(3):422-9.

View in: PubMed
Bang CN, Gerdts E, Aurigemma GP, Boman K, Dahl?f B, Roman MJ, K?ber L, Wachtell K, Devereux RB. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2013 Oct; 31(10):2060-8.

View in: PubMed
Arnold AC, Okamoto LE, Gamboa A, Shibao C, Raj SR, Robertson D, Biaggioni I. Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure. Hypertension. 2013 Mar; 61(3):701-6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals